Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Anaplastic large cell lymphoma

Anaplastic large cell lymphoma

1 published article · Updated continuously

Clinical Trial Landscape

Clinical Trials for Anaplastic large cell lymphoma

34 trials tracked for Anaplastic large cell lymphoma: 1 in phase 3 or 4 and 1 with published results. The most-cited published study has 728 citations.

34Trials tracked
1Phase 3 & 4
0Recruiting
1With published results
Phase distribution
Phase 3 1 Phase 2 28 Phase 1 3 Other / NA 2
  1. Phase 3 ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas Completed · 728 cited
  2. Phase 2 Tacrolimus and Mycophenolate Mofetil in Preventing Graft-Versus-Host Disease in Patients Who Have Undergone Total-Body Irradiation With or Without Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant for Hematologic Cancer Completed
  3. Phase 2 Tipifarnib in Treating Patients With Relapsed or Refractory Lymphoma Completed
  4. Phase 2 Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies Completed
  5. Phase 2 Study of BGB-A317 in Participants With Relapsed or Refractory Mature T- and NK-cell Neoplasms Completed
  6. Phase 2 Ixabepilone in Treating Patients With Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma Completed
Show 28 more trials
  1. Phase 2 17-AAG in Treating Patients With Relapsed or Refractory Anaplastic Large Cell Lymphoma, Mantle Cell Lymphoma, or Hodgkin's Lymphoma Completed
  2. Phase 2 Bendamustine Hydrochloride, Etoposide, Dexamethasone, and Filgrastim For Peripheral Blood Stem Cell Mobilization in Treating Patients With Refractory or Recurrent Lymphoma or Multiple Myeloma Completed
  3. Phase 2 Alisertib in Treating Patients With Relapsed or Refractory Peripheral T-Cell Non-Hodgkin Lymphoma Completed
  4. Phase 2 Haploidentical Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancer Completed
  5. Phase 2 Combination Chemotherapy and Pralatrexate as First-Line Therapy in Treating Patients With Non-Hodgkin Lymphoma Completed
  6. Phase 2 Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematological Malignancies Completed
  7. Phase 2 Belinostat and Yttrium Y 90 Ibritumomab Tiuxetan in Patients W/Relapsed Aggressive B-Cell NHL Completed
  8. Phase 2 Deferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic Malignancies Completed
  9. Phase 2 Alemtuzumab, Fludarabine Phosphate, and Low-Dose Total Body Irradiation Before Donor Stem Cell Transplantation in Treating Patients With Hematological Malignancies Completed
  10. Phase 2 Panobinostat and Everolimus in Treating Patients With Recurrent Multiple Myeloma, Non-Hodgkin Lymphoma, or Hodgkin Lymphoma Completed
  11. Phase 2 Everolimus and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma Completed
  12. Phase 2 Study of Akt Inhibitor MK2206 in Patients With Relapsed Lymphoma Completed
  13. Phase 2 Oral Clofarabine for Relapsed/Refractory Non-Hodgkin Lymphoma Completed
  14. Phase 2 Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer Completed
  15. Phase 2 Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid Tumors Completed
  16. Phase 2 Dose-Adjusted EPOCH Chemotherapy and Rituximab (CD20+) in Previously Untreated Aggressive Non-Hodgkin's Lymphoma Completed
  17. Phase 2 Venetoclax and Romidepsin in Treating Patients With Recurrent or Refractory Mature T-Cell Lymphoma Completed
  18. Phase 2 Iodine I 131 Tositumomab, Etoposide and Cyclophosphamide Followed by Autologous Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma Completed
  19. Phase 2 Sorafenib Tosylate in Treating Patients With Recurrent Aggressive Non-Hodgkin's Lymphoma Completed
  20. Phase 2 Donor T Cells After Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies Completed
  21. Phase 2 Gemcitabine Hydrochloride, Carboplatin, Dexamethasone, and Rituximab in Treating Patients With Previously Treated Lymphoid Malignancies Completed
  22. Phase 2 Vorinostat, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Lymphoma or Previously Untreated T-Cell Non-Hodgkin Lymphoma or Mantle Cell Lymphoma Completed
  23. Phase 2 Panobinostat in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma Completed
  24. Phase 1 Interleukin-15 (IL-5) in Combination With Avelumab (Bavencio) in Relapsed/Refractory Mature T-cell Malignancies Completed
  25. Phase 1 Study of MLN8237 in Participants With Advanced Hematological Malignancies Completed
  26. Phase 1 A Phase 1 Study in Patients With Relapsed or Refractory Hodgkin Lymphoma or Systemic Anaplastic Large Cell Lymphoma Completed
  27. N/A Fludarabine Phosphate, Melphalan, Total-Body Irradiation, Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Bone Marrow Failure Disorders Completed
  28. N/A Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenolate Mofetil in Treating HIV-Positive Patients With or Without Cancer Completed

Showing the 34 most-cited and recently-updated of 34 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
CD30-directed therapy, JAK/STAT inhibition, and checkpoint blockade offer potential options for ALK-negative anaplastic large cell lymphoma
Oncology Sys. Review
CD30-directed therapy, JAK/STAT inhibition, and checkpoint blockade offer potential options for ALK-negative anaplastic large cell lymphoma Newer treatment paths for young people with a rare lymphoma
This mini-review explores the biological heterogeneity and emerging therapeutic landscape of ALK-negative anaplastic large cell lymphoma in …
Doctors are looking at new ways to treat anaplastic large cell lymphoma in children and young adults using targeted therapies.
Frontiers Aug 2, 2026